Cargando…

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer

Preclinical data support a role for the IL-6/JAK2/STAT3 signaling pathway in breast cancer. Ruxolitinib is an orally bioavailable receptor tyrosine inhibitor targeting JAK1 and JAK2. We evaluated the safety and efficacy of ruxolitinib in patients with metastatic breast cancer. This was a non-randomi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stover, Daniel G., Gil Del Alcazar, Carlos R., Brock, Jane, Guo, Hao, Overmoyer, Beth, Balko, Justin, Xu, Qiong, Bardia, Aditya, Tolaney, Sara M., Gelman, Rebecca, Lloyd, Maxwell, Wang, Yu, Xu, Yaomin, Michor, Franziska, Wang, Vivian, Winer, Eric P., Polyak, Kornelia, Lin, Nancy U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935675/ https://www.ncbi.nlm.nih.gov/pubmed/29761158 http://dx.doi.org/10.1038/s41523-018-0060-z

Ejemplares similares

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021)

Copy Number Variation in Inflammatory Breast Cancer
por: Hazra, Aditi, et al.
Publicado: (2023)

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019)

Non-cell autonomous tumor-growth driving supports sub-clonal heterogeneity
por: Marusyk, Andriy, et al.
Publicado: (2014)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
por: Goker Bagca, Bakiye, et al.
Publicado: (2020)

The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes
por: Griveau, Audrey, et al.
Publicado: (2020)

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
por: Smith, Paul, et al.
Publicado: (2021)

New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
por: Marcuzzi, Annalisa, et al.
Publicado: (2022)

JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
por: Stevens, Laura E., et al.
Publicado: (2023)

Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib
por: Shide, K, et al.
Publicado: (2017)

The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice
por: Shaker, Mohamed E., et al.
Publicado: (2022)

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
por: Van Den Neste, Eric, et al.
Publicado: (2018)

P1428: IMPLICATIONS OF THE RUXOLITINIB (JAK1/JAK2 INHIBITOR) ON GRAFT-VERSUS-LEUKAEMIA EFFECT MEDIATED BY THE NK CELL.
por: Durán, C., et al.
Publicado: (2022)

Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm
por: Langmuir, Peter, et al.
Publicado: (2020)

The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis
por: Overstreet, A.M., et al.
Publicado: (2018)

Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report
por: FAN, Birao, et al.
Publicado: (2022)

Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2(V617F) cells
por: Machado-Neto, João Agostinho, et al.
Publicado: (2015)

Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation
por: Cattalini, Marco, et al.
Publicado: (2021)

Combined Ruxolitinib and Venetoclax Treatment in a Patient with a BCR-JAK2 Rearranged Myeloid Neoplasm
por: Lap, Coen J., et al.
Publicado: (2021)

Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome
por: Huarte, Eduardo, et al.
Publicado: (2021)

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
por: Verstovsek, Srdan, et al.
Publicado: (2014)

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
por: Helbig, Grzegorz, et al.
Publicado: (2017)

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
por: Vannucchi, Alessandro M., et al.
Publicado: (2020)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures
por: Singer, Jack W., et al.
Publicado: (2019)

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
por: Hammersen, J., et al.
Publicado: (2023)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells
por: Mazzacurati, Lucia, et al.
Publicado: (2015)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Ruxolitinib inhibits the proliferation and induces the apoptosis of MLL-r ALL cells through inactivating JAK/STAT signaling pathway
por: Liao, Xiong-Yu, et al.
Publicado: (2023)

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
por: Tolaney, Sara M., et al.
Publicado: (2015)

Ruxolitinib: Thrombocytopenia following compassionate use of ruxolitinib: 2 case reports
Publicado: (2022)

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS
por: Harrison, C., et al.
Publicado: (2022)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS)
por: Wen, Sai, et al.
Publicado: (2022)

IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2(V617F)-positive myeloproliferative neoplasms
por: de Melo Campos, Paula, et al.
Publicado: (2016)

Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib
por: Sobotta, Svantje, et al.
Publicado: (2017)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F(+) cell models
por: De Marinis, Elisabetta, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uo2h2c0r5aitdfk7latmphbqte